Dott. Carlo Garufi Oncologia Medica C Istituto Regina Elena, Roma Scuola Mediterranea di Oncologia “Actigrafia nel tumore della mammella” Roma 28.11.2008.

Slides:



Advertisements
Similar presentations
Dr Andrea Micheli Descriptive Epidemiology and Health Planning Unit Istituto Nazionale Tumori Milan WP-10 - CANCER EXCHANGE OF INFORMATION ON THE PROJECT.
Advertisements

THE EFFICACY OF MULTI-CONVERGENT THERAPY
Multidisciplinary Approach to GE junction tumors MOTP Academic Half Day Sep PMH Boardroom Dr. Darling Dr. Wong Thoracic OncologyRadiation Oncology.
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
PreOP XRT: Oral fluoropyrimidines in randomized trials
Mario Scartozzi Clinica di Oncologia Medica Ancona HIGHLIGHTS IN COLORECTAL CANCER MANAGEMENT TREATMENT OF METASTATIC DISEASE.
FOLFOXIRI plus bevacizumab (bev) vs FOLFIRI plus bev
Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.
Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Metastatic Gastric Cancer
MOSAIC Stage ll+lll FOLFOX4 LV5FU2 Randomize. DFS DFS (months) Hazard ratio: 0.77 [0.65 – 0.92] p < 0.01 FOLFOX (n=1123) 77.9% LV5FU2 (n=1123) 72.8% FOLFOX.
A Phase III Trial Comparing FULV to FULV + Oxaliplatin in Stage II or III Carcinoma of the Colon: Results of NSABP-C-07 Norman Wolmark, MD Colorectal Cancer.
Clinical prognostic factors Claus-Henning Köhne Klinik für Onkologie und Hämatologie ESMO 21. September 2009 Berlin Germany.
1 N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Patients with Advanced Colorectal Carcinoma Previously Treated.
Cancer Related Fatigue Suzy Coughlan Specialist Dietitian in Oncology.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant ovarian cancer Michael Friedlander Phyllis Butow, Martin.
, START UP MEETING FOR STAGE 2. Response Rates in Phase 3 Trials Chemotherapy Response rates % Liposomal doxorubicin Gemcitabine 5-9 Gemcitabine.
N ational S urgical A djuvant B reast and B owel P roject.
Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up.
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
Capecitabine versus Bolus 5-FU/Leucovorin as Adjuvant Therapy for Colon Cancer: X-ACT Trial Results James Cassidy, MD Colorectal Cancer Update Think Tank.
Current Opinion in the Colorectal Cancer Treatment
Poster #382 XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated.
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
*University Hospital Gasthuisberg, Leuven, Belgium
Effect of Early Palliative Care (PC) on Quality of Life (QOL), Aggressive Care at the End-of- Life (EOL), and Survival in Stage IV NSCLC Patients: Results.
Barb Supanich, RSM, MD, FAAHPM Holy Cross IP Palliative Care Team November 11, 2010.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
T Andre, E Quinaux, C Louvet, E Gamelin, O Bouche, E Achille, P Piedbois, N Tubiana-Mathieu, M Buyse and A de Gramont. Updated results at 6 year of the.
0 Adjuvant FOLFIRI +/- Cetuximab in Patients with Resected Stage III Colon Cancer NCCTG Intergroup Phase III Trial N0147 Jocelin Huang, Daniel J Sargent,
Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU- leucovorin as 1st line chemotherapy for metastatic.
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
Health-related quality of life in patients with oesophageal- and gastric cancer Lovisa Backemar, MD Surgical Care Sciences Department of Molecular Medicine.
Preliminary Results from a Phase II study of FOLFIRI and Bevacizumab as First Line Treatment for Metastatic Colorectal Cancer (Abstract #3579) S. Kopetz,
Symptom control in patients with recurrent ovarian cancer Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant.
Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.
Quality of life and its health- relations. Definitions.
Quality of Life (QOL) & Patient Reported Outcomes (PRO) Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research Group, DCP, NCI, NIH,
The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB Nadine A. Jackson, Charles S.
Gemcitabine With or Without Cisplatin in Patients with Advanced or Metastatic Biliary Tract Cancer (ABC): Results of a Multicentre, Randomized Phase III.
Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.
Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.
Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
Cetuximab plus FOLFIRI 1 st -line in patients (pts) with metastatic colorectal cancer (mCRC): A quality of life (QoL) analysis of the CRYSTAL trial G.
Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.
The impact of age on outcome in early-stage breast cancer 방사선종양학과 R2. 최진현.
Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
CCO Independent Conference Coverage
Direttore UOC di Oncologia Medica
CCO Independent Conference Coverage
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
The Relationship Between Mental and Physical Health
Is there a role for adjuvant oxaliplatin in rectal cancer? - YES! -
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
Alan P. Venook, MD University of California, SF
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,
Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (MRC FOCUS)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.
2 or 3 Year DFS is an Appropriate Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with Fluoropyrimidines with or without Oxaliplatin or Irinotecan.
Schema of the exploratory analyses (RAS wild-type population)
Presentation transcript:

Dott. Carlo Garufi Oncologia Medica C Istituto Regina Elena, Roma Scuola Mediterranea di Oncologia “Actigrafia nel tumore della mammella” Roma

BREAST CANCER Fatigue is the most prevalent and distressing symptom experienced by pts receiving adjuvant ChT for early stage BC Higher fatigue levels are related to sleep maintenance problems and low daytime activity in pts after ChT Sparse data available about circadiam rhythms alteration and fatigue prior to chemotherapy

Ample evidence suggest doctors might systematically misjudge patients' perception levels of symptoms or related important aspects of their illness….and there is wide agreement that patient themselves should be the primary source of information. (Slevin et al 1988; Sprangers et al. 1992; Da Silva et al. 1996; Stephens et al Passik et al. 1998; Fayers et al. 2000; Wilson et al. 2000; Titzer et al. 2001) Is the doctor’s view a reliable measure of patients HRQOL?

Cancer Related Fatigue “distressing, persistent, subjective, sense of tiredness or exhaustion related to cancer or to cancer treatment that is not proportional to recent activity and interferes with usual functioning” NCCN 2006

(Cleeland, et al, 2004)

Anxiety Pain Lower sleep quality Physical Inactivity Poor PS Cancer Related Fatigue

REST/ACTIVITY RHYTHM: THE ACTIGRAPH Piezo-electric accelerometer; Number of wrist accel./minute; Allows continuous recording, over a long time period. Parameters: 24-h pattern and alternance of rest and activity.

Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC C. Garufi et al. ASCO 2005 The data confirmed the strong and indipendent prognostic value of the RAR for the survival of MCC patients in a multicentre randomized trial

Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin : an international multicenter study (EORTC 05963). P.F. Innominato et al. ASCO 2005 The correlation between RAR and Global QoL and symptom scores as fatigue and anorexia was confirmed for the first time in a multicenter setting

5FU/FA FFL Garufi et al Anticancer Drugs ‘01 CPT-11 + FF 5-16 Garufi et al Cancer ‘01 EORTC CPT-11  + FFL  5FU/FA  Garufi et al EJC ‘97 Studi di Cronotherapia presso l’IRE CPT-11 bolus + FFL crono Garufi et al BJC ‘03 CPT-11 crono vs standard + FF 4-10 Garufi et al EJC ’06

VariablesHazard ratio (HR)95% Confidence IntervalP-value UNIVARIATE Sex Performance Status < Agen.s. Site of primary tumorn.s Number site involved Qol parameters Physical Functionig Emotional Functioning Social Functioning Fatigue < Pain Nausea/vomitingn.s. Appetite Loss Costipationn.s. Diarrhoean.s. Global QoL < MULTIVARIATE Performance Status < Global QoL < Analisi Univariata e Multivariata sec Cox per la Sopravvivenza

Individual patient circadian rhythm assessment by actigraphy. Cortisol Ratio (Slope) Serum TGF-  Serum IL-6 Symptoms Robust Rhythm * (autocorrelation >0.47) 1.72 (Steep) Low Less fatigue, appetite loss. Dampened Rhythm (autocorrelation <0.35) 1.60 (Flat) High More fatigue and appetite loss. * p = < 0.05 Correlation: Rest/activity and Cortisol rhythms, TGF-  and cytokines, and symptoms. Clin Cancer Res 2005; 11(5):

StudyPopulationStudy timingVariableMethodsFindings Ancoli-Israel 2006 n=85 (34-79y) Stage I-III Prior ChTFatigue Obj/Subj sleep quality Circadian rhythm MFSI, PSQI Actigraph Significant correlation (p>.0001) between subjective measure of sleep and fatigue Andrykowski 1998 n=88 (35-76y) Stage I-IIIA After ChTFatigue Sleep quality CFS, PFS, PSQISignificant correlation between fatigue and sleep quality Berger 1998 n=72 (33-69y) Stage I/II During ChTFatigue Activity and rest cycle PFS Actigraph Fatigue and disrupted activity/sleep inversely related (p<.05) Berger 1999 n=72 (33-69y) Stage I/II During ChTFatigue Circadian activity/rest indicators PFS Actigraph Reduced daytime activity, increased daytime sleep, and increase nighttime awakening were associated with increased fatigue Berger 2000 n=14 (32-69y) Stage I/II During/ after ChTFatigue Activity and rest cycle Actigraph, MSD, SES, PFS Low activity, disrupted sleep and increased distress werecorrelated with fatigue Bower 2000 n=1957 (mean 55y) Stage 0- III After ChTFatigue Sleep disturbance Energy fatigue subscale MOSSS Fatigue is strongly associated with sleep disturbance Broeckel 1998 n=61 (29-75y) After ChTFatigue Sleep quality FS from PMS, PSQI Severe fatigue significantly correlates with poorer sleep quality (p<.05) and sleeping during the day (p<.001) Curran 2004 n=25 (28-63y) Stage 0-III After ChTFatigue Sleep duration Likert scale, diary sleep duration Fatigue after treatmento not correlates with sleep duration Jacobsen 1999 n=54 (28-77y) stage I-III During ChTFatigue Sleep problems MSASSleep problems associated with significant increase in fatigue severity Okuyama 2000 n=134 (28-86y) Stage 0-III After surg, ChT, RT Fatigue Sleep CFS, Likert scaleInsufficient sleep is one of the determinat of fatigue Roscoe 2002 n=78 (34-79y) During ChtFatigue Circadian sleep rhythm FSC Actigraph Increased circadian rhythms disruption correlates with increased fatigue

85 women with stage I-IIIA breast cancer evaluation 7 days prior adjuv (n=72) or neoadjuv (n=13) ChT  Women report fatigue and disturbed sleep before ChT begins  Significant relationship between subjective poor sleep and fatigue and/or reduction of functional outcome  Objective measures confirm disrupted and disturbed sleep  However no significant correlation between objective sleep variable at night or during the day and fatigue and/or functional outcome  Although their circadian rhythms are robust, pts with more delayed rhythms experience more daily disfunction secondary to fatigue  Possible correlation between depression and fatigue Supp Care Cancer 2006, 12: 201-9

219 women with stage I-IIIA breast cancer Evaluation 48 h prior adjuvant ChT Measure of sleep (PSQI), fatigue (PFS) and circadian rhythms (Actigraph) J Pain Sympt Manag 2007, 33:

Berger et al., J Pain Sympt Manag 2007

Change in the actigraphy measures over time were significantly correlated with chenges in fatigue, mood, and depression Supp Care Cancer 2002, 10: Circadian rhythm Fatigue Depression Mood

Roscoe et al., Supp Care Cancer 2002

Conclusions Fatigue correlates with sleep distrubance Actigraph can be used to monitor circadian rhythms alteration Strategy of intervention through light exposure or phisical activity could help in preventing CRF